sr141716 has been researched along with Ascites in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernardi, M; Caraceni, P; Croci, T; Domenicali, M; Giannone, F; Pertosa, AM; Principe, A; Trevisani, F; Zambruni, A | 1 |
| Bifulco, M; D'Alessandro, A; Galgani, M; Gazzerro, P; Laezza, C; Malfitano, AM; Matarese, G | 1 |
2 other study(ies) available for sr141716 and Ascites
| Article | Year |
|---|---|
Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis.
Topics: Animals; Ascites; Blood Pressure; Carbon Tetrachloride; Cardiac Output; Diuresis; Dose-Response Relationship, Drug; Kidney; Liver Cirrhosis, Experimental; Male; Natriuresis; Piperidines; Pyrazoles; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1; Renal Circulation; Rimonabant; Sodium; Sodium, Dietary; Time Factors; Vascular Resistance | 2009 |
The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ascites; Cell Cycle; Cell Line, Tumor; Cell Survival; Female; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Sarcoma | 2012 |